全文获取类型
收费全文 | 31406篇 |
免费 | 2565篇 |
国内免费 | 1772篇 |
专业分类
耳鼻咽喉 | 29篇 |
儿科学 | 525篇 |
妇产科学 | 149篇 |
基础医学 | 4536篇 |
口腔科学 | 94篇 |
临床医学 | 2743篇 |
内科学 | 13089篇 |
皮肤病学 | 149篇 |
神经病学 | 250篇 |
特种医学 | 544篇 |
外国民族医学 | 4篇 |
外科学 | 1027篇 |
综合类 | 5829篇 |
现状与发展 | 11篇 |
预防医学 | 2541篇 |
眼科学 | 30篇 |
药学 | 2324篇 |
11篇 | |
中国医学 | 1324篇 |
肿瘤学 | 534篇 |
出版年
2024年 | 34篇 |
2023年 | 396篇 |
2022年 | 697篇 |
2021年 | 887篇 |
2020年 | 924篇 |
2019年 | 1020篇 |
2018年 | 926篇 |
2017年 | 1024篇 |
2016年 | 1240篇 |
2015年 | 1273篇 |
2014年 | 1970篇 |
2013年 | 2097篇 |
2012年 | 1876篇 |
2011年 | 2250篇 |
2010年 | 1704篇 |
2009年 | 1552篇 |
2008年 | 1568篇 |
2007年 | 1679篇 |
2006年 | 1625篇 |
2005年 | 1326篇 |
2004年 | 1141篇 |
2003年 | 1042篇 |
2002年 | 909篇 |
2001年 | 933篇 |
2000年 | 765篇 |
1999年 | 615篇 |
1998年 | 518篇 |
1997年 | 495篇 |
1996年 | 438篇 |
1995年 | 444篇 |
1994年 | 380篇 |
1993年 | 314篇 |
1992年 | 275篇 |
1991年 | 211篇 |
1990年 | 169篇 |
1989年 | 140篇 |
1988年 | 145篇 |
1987年 | 116篇 |
1986年 | 93篇 |
1985年 | 102篇 |
1984年 | 85篇 |
1983年 | 51篇 |
1982年 | 60篇 |
1981年 | 50篇 |
1980年 | 54篇 |
1979年 | 33篇 |
1978年 | 38篇 |
1977年 | 23篇 |
1976年 | 9篇 |
1973年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Hepatitis C virus (HCV) infection is a major health care issue in liver and kidney transplantation. Besides negatively affecting both patient and graft survival, HCV is associated with a heightened risk for new onset diabetes mellitus (NODM). The mechanisms underlying the diabetogenicity of HCV are complex but are likely to involve insulin resistance caused by inhibitory actions of the virus on insulin regulatory pathways in the liver. The resultant glucose dysregulation is an important determinant of increased morbidity and mortality in liver and kidney recipients. This review highlights the concerns for outcomes in HCV-positive liver and kidney transplant patients with particular focus on the interrelationship between hepatitis C and diabetes. Data about the potential role of calcineurin inhibitors, corticosteroids and mycophenolate mofetil in HCV infection and HCV-associated NODM will also be discussed. 相似文献
12.
13.
92例重型肝炎并发自发性细菌性腹膜炎的诊断与治疗 总被引:2,自引:1,他引:1
目的探讨重型肝炎并发自发性细菌性腹膜炎(SBP)的诊断和抗生素使用。方法回顾性分析2002年7月~2005年6月间收治的92例并发SBP的重型肝炎患者的临床资料。结果92例患者中,发热72例(78.26%),腹胀85例(92.39%),腹痛38例(41.30%),反跳痛35例(38.04%),83例(90.21%)外周血中性粒细胞(PMN)分类≥0.75,40例(45.98%)腹水PMN计数≥250个/mm3,79例(90.80%)腹水PMN比值≥0.50,11例(12.00%)腹水细菌培养阳性,共分离出细菌17株,G-杆菌占52.9%(9/17),其对头孢曲松、头孢哌酮、头孢他啶、左旋氧氟沙星及泰能敏感,对丁胺卡那、氧哌嗪青霉素敏感性较低。临床治疗显示,联合使用头孢他啶和甲硝唑效果较好,并较少出现继发真菌感染。结论重型肝炎并发SBP患者的临床表现不典型,腹水培养阳性率低,外周血和腹水PMN比值是诊断SBP比较可靠的参数。治疗SBP,可首选二联使用头孢他啶与甲硝唑,疗程约10~14日。 相似文献
14.
MASAFUMI IKEDA SHIGETOSHI FUJIYAMA MOTOHIKO TANAKA MICHIO SATA TATSUYA IDE HIROSHI YATSUHASHI HIROSHI WATANABE 《Journal of gastroenterology and hepatology》2006,21(1):122-128
Background and Aim: This study investigated the clinical features of hepatocellular carcinoma in patients with sustained virological response to interferon for hepatitis C viral (HCV) infection. Methods: A total of 7715 patients with HCV infection were treated with interferon and followed up for more than 1 year after withdrawal of interferon in 64 Japanese hospitals and clinics between July 1988 and August 2001. Sustained virological response was obtained in 2515 (32.6%) patients. Of these 2515 patients, clinical data were collected for 38 patients in whom hepatocellular carcinoma developed. Sustained virological response was defined as HCV RNA negativity more than 6 months after the termination of interferon. Results: All patients were HCV RNA negative at the time of diagnosis of hepatocellular carcinoma. The median period until the detection of hepatocellular carcinoma was 4.7 years (range 1.4–9.0 years). There were significant improvements in hepatic function including serum albumin, aspartate aminotransferase, alanine aminotransferase, indocyanine green test, platelet count and histological activity grade in comparison with those before interferon therapy and at the onset of hepatocellular carcinoma. The maximum tumor size in patients without medical follow‐up for 1 year or more (median: 60 mm) was significantly larger than in patients who were periodically followed up for 6 months or less (median: 25 mm) (P = 0.002). Conclusions: The present findings emphasize the importance of regular medical follow up of patients with HCV infection, as even patients showing a sustained virological response to interferon and in whom hepatic function has improved have the potential to develop hepatocellular carcinoma. 相似文献
15.
A. Biglino M. Depaoli G. Cariti D. Giacobbi P. Gioannini 《European journal of epidemiology》1988,4(2):246-250
A cross-sectional, longitudinal study was undertaken on a group of acute non-A, non-B hepatitis patients, as well as on a control group of hepatitis B patients, in order to assess both the prevalence of the most important factors favoring infection, and the relevance of these factors in promoting evolution towards chronic liver disease. Exposures to unknown risk factors were present in 47.4% of acute non-A, non-B infections, followed by blood transfusions (17.9%), sporadic exposures (17.9%) and drug addiction (16.6%). Unknown as well as sporadic exposures showed a greater prevalence in control population if compared to non-A, non-B cases, while drug addiction was equally represented in the two groups, and blood transfusion nearly absent from control group. The risk of evolution to chronic liver disease was about 13 times greater in non-A, non-B group than in controls, with the greatest risk for drug addicts and the lowest for patients with unknown exposures. Among patients with known exposures, the lowest risk of chronic hepatitis was observed in post-transfusion and in sporadic cases, while the greatest was observed in drug addicts.Corresponding author. 相似文献
16.
17.
18.
目的探讨复方丹参注射液联合干扰素治疗慢性乙肝患者的疗效。方法110例慢性乙肝患者,按随机方法分成①对照组30例,应用普通保肝药物治疗,疗程6个月;②丹参组30例,应用复方丹参注射液(每ml含丹参、降香各1g)30ml加入10%葡萄糖溶液300ml中静脉注射1个月;③IFN组30例,应用IFN—α 3MU,隔日一次肌内注射,3个月;④联合组20例,应用复方丹参注射液30ml加10%葡萄糖溶液300ml静脉注射1个月,IFN-α 3MU,隔日一次肌内注射,3个月。丹参组,IFN组和联合组保肝药物治疗同对照组。四组病例在性别、年龄、病程,治疗前肝功能等方面均无统计学差异。治疗前检测肝功能,肝炎病毒标志,血清HA、IV—C、PCI—Ⅱ,部分病例进行肝穿病理检查。治疗开始后每月检测肝功能,3个月(治疗后)和6个月(随访时)时检测血清HA、IV—C、PCⅢ及乙肝病毒标志,治疗后1年行肝穿病理检查。结果治疗前四组患者血清HA、PCⅢ、IV—C水平无统计学差异;治疗后丹参组、IFN组、联合组血清HA、FCⅢ、IV—C水平较治疗前及对照组有不同程度的降低。结论复方丹参注射液联合IFN治疗可使血清HA、PCⅢ、IV—C有明显下降,肝组织病理改变明显改善,为目前有效的慢性乙肝治疗措施。 相似文献
19.
免疫组化法检测非甲-非庚型肝炎患者肝组织中输血传播病毒 总被引:1,自引:1,他引:0
目的 检测非甲-非庚型肝炎患者肝组织输血传播病毒(TTV)感染状况,TTV感染与肝组织炎症程度 及与血液学指标的相关性。方法 应用免疫组织化学法检测52例非甲-非庚型肝炎患者肝组织中TTV,并经原位 杂交证实;对TTV阳性和阴性组的血液学生化指标,诸如血清丙氨酸转氨酶(ALT)、血清天冬氨酸转氨酶(AST)、血 清总胆红素(TBIL)、白蛋白(ALB)、γ 球蛋白(γ G)、凝血酶原活动度(PTA)及组织学活动指数(HAI)进行了比较。 结果 非甲-非庚型肝炎患者肝组织中TTV抗原(TTVAg)阳性15例,检出率为28.8%;阳性物质主要定位于肝细 胞浆内,呈棕黄色细小颗粒,偶见肝细胞核内有表达;TTV阳性表达细胞呈单个、散在或片簇状分布;TTVAg阳性的 组织切片经苏木素-伊红(HE)染色后,可观察到病毒性肝炎的一些病理变化,如肝细胞胞浆疏松化、气球样变、嗜酸 样变、灶性坏死、凋亡、小叶内及汇管区炎细胞浸润;从15例TTVAg阳性病例中任选10例进行TTV DNA原位杂交 检测,结果8例阳性,二者符合率80.0%;同时对5例免疫组化TTVAg阴性肝组织进行TTV DNA原位杂交检测,结 果5例均为阴性,二者符合率100%;TTVAg阳性组ALT、AST、TBIL、γ G均值均高于TTVAg阴性组,ALB、PTA 均值均低于TTVAg阴性组,但两组比较差异无统计学意义(P>0.0 相似文献
20.
心先安佐治小儿病毒性心肌炎临床疗效分析 总被引:1,自引:0,他引:1
目的:分析心先安佐治小儿病毒性心肌炎的临床疗效。方法:136例病毒性心肌炎患儿随机分为治疗组及对照组,在相同的 基础治疗条件下,治疗组应用心先安2~5mg kg,加液静滴,每天2次。结果:心先安组;痊愈51例(75%),好转12例(17.65%),无效5例(7. 35%),总有效92.65%。对照组痊愈41例(60.29%),好转14例(20.59%),无效13例(19.12%),总有效80.88%。两组相比、差异有显著性 (x2=4.09,P<0.005)。结论:心先安治疗小儿病毒性心肌炎疗效确切,且安全、可靠。 相似文献